Amplia Therapeutics Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher J. Burns
- Full Time Employees
- 8
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 90 William Street Melbourne VIC Australia 3000
- IPO Date
- Dec 20, 2013
- Website
- ampliatx.com
- Similar Companies
- Business
- Amplia Therapeutics Limited (ASX:ATX) is an Australian clinical-stage biotechnology company that develops focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrotic diseases. The company focuses on narmafotinib (AMP945), a potent, selective, orally available FAK inhibitor in Phase 1b/2a clinical trials including the ACCENT trial combining narmafotinib with gemcitabine and Abraxane for first-line advanced pancreatic ductal adenocarcinoma, where it has achieved a confirmed objective response rate of 33% and interim median progression-free survival of 7.6 months; the AMPLICITY trial combining narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer under an open U.S. IND with sites in Australia and the United States; and additional applications in ovarian cancer, idiopathic pulmonary fibrosis, other solid tumors, and fibrotic indications. It also advances AMP886, a second-generation FAK inhibitor in preclinical development for oncology and chronic fibrosis. Amplia Therapeutics, founded in 2000 and headquartered at Level 5, 90 William Street in Melbourne, Australia, formerly operated as Innate Immunotherapeutics Limited until renaming in September 2018. Recent developments include positive U.S. FDA feedback in November 2025 supporting a Phase 2b/3 trial design for narmafotinib with gemcitabine and Abraxane featuring a two-dose comparison leading to pivotal Phase 3; IND clearance and first patient dosing in the FOLFIRINOX combination trial in September 2025; uplisting to the U.S. OTCQB Venture Market under INNMF in October 2025 to enhance U.S. investor access; U.S. patent allowance for narmafotinib's specific salt and crystal form extending protection to at least 2040 across multiple jurisdictions; a A$3.7 million Australian R&D tax rebate; and a A$27.5 million capital raise in July 2025 comprising A$25 million from institutional and sophisticated investors plus A$2.5 million from others to fund ongoing trials, investigator-initiated studies in pancreatic and ovarian cancer, and regulatory interactions. The company targets fibrotic cancers such as pancreatic and ovarian alongside chronic fibrotic diseases like idiopathic pulmonary fibrosis, operating primarily from Australia with expanding U.S. clinical and capital markets presence.
Company News
Amplia Therapeutics partners with Lilly on lung cancer combination trial
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
Amplia Announces Publication of New FAK Inhibitor Patent Application
Amplia Announces Appointment of Brett Carter to Board
Amplia Announces Changes to Board's Leadership Roles
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
Accent Trial Mature Data Presented at International Conference
Altona Rare Earths shares jump 11% as gallium results exceed expectations at Mozambique project
Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer
X‑Energy files to go public on the Nasdaq, eyes $300M raise
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
Additional Confirmed Response Reported as Part of Amplia Investor Presentation